The seventh call for applications will be open until January 15, 2021, 23:59 CET (Expired)
MINDED research activities have already started on January 1st, 2018 and currently involve 17 fellows. The program is coordinated by IIT and funded by the European Commission within the Marie Sklodowska-Curie Actions (MSCA) framework.
Istituto Italiano di Tecnologia – IIT is seeking for 7 research fellows to be involved in the highly interdisciplinary program within the Marie Sklodowska-Curie COFUND project “MultIscale precision therapies for NeuroDEvelopmental Disorders - MINDED”, funded by the European Commission with the Grant Agreement n. 754490 . The MINDED program will establish a new class of scientists, trained to integrate their knowledge over the fields of nanomedicine, neuroscience and robotics, with the aim of developing new approaches for the diagnosis, imaging and treatment of neurodevelopmental disorders. The program started in January 1st, 2018 at the IIT Central Lab in Genoa (Italy) and involves 18 more institutions based in Italy, Europe, Israel and USA. The MINDED project was awarded € 3.4 million from the European Commission, and co-funded by IIT for a total investment of € 6.8 million.
Neurodevelopmental disorders (NDDs) represent a huge burden for patients, their families and the overall society. In the European Union, the incidence of autism spectrum disorders is on the rise with more than 100 cases for 10,000 children. This is about ten times larger than the incidence of brain and central nervous system tumors in children. In addition, the lack of effective therapies and the need for lifelong interventions and assistance dramatically affect the national health systems.
MINDED will use a multiscale technology approach, integrating Nanomedicine, Molecular Neurosciences and Cognitive Neuroscience Robotics, for the development of novel diagnostic, imaging and therapeutic interventions for NDDs. Whilst Neuroscience investigates the causes of NDDs identifying biological targets for new and more effective therapies, Nanomedicine allows us to develop devices for the precise and patient-specific delivery of novel therapeutic molecules and contrast agents. Early detection will be improved through the application of robotics for assessing quantitatively sensorimotor and cognitive deficits in NDD patients. Selected MINDED fellows will also benefit of a specific training in business development, to facilitate the clinical integration of biomedical products, through internships at the European Medicines Agency and various EU and US companies.
MINDED fellows will be appointed with a 2-years contract. Applicants should hold a Doctoral Degree (or at least 4-years of full-time equivalent research experience), be fluent in English, write a research proposal, and have outstanding career record. Following the guidelines of the Marie Sklodowska-Curie Actions, applicants must have not resided or carried out their main activity (work, studies, etc.) in Italy for more than 12 months in the last 3 years preceding January 15, 2021. The eligibility criteria can be found here.
MINDED is coordinated by Istituto Italiano di Tecnologia in collaboration with SISSA- Scuola Internazionale Superiore di Studi Avanzati and University of Bologna in Italy; University of Paris-Sud and CNRS in France; Durham University, University College of London and European Medicines Agency in UK; Universidade do Minho in Portugal; University of Heidelberg, Max Planck Institute of Psychiatry and Forschungszentrum Jülich GmbH in Germany; Radboud University Medical Center in the Netherlands; Ecole Polytechnique Federale de Lausanne and Centre Hospitalier Universitair Vaudois CHUV in Switzerland; Charles River Laboratory in Finland; Tel Aviv University in Israel; Universitat Pompeu Fabra Barcelona in Spain and Stanford University in USA. The project coordinator is Dr. Paolo Decuzzi, head of Nanotechnology for Precision Medicine Lab at IIT and European Research Council (ERC) grantee.
IIT was established in 2003 and successfully created a large-scale infrastructure in Genova and a network of 10 state-of-the-art laboratories countrywide with an international staff of about 1700 people from more than 60 countries. IIT's research endeavour focuses on high-tech and innovation, representing the forefront of technology with possible application from medicine to industry, material science, robotics, life sciences and nano-biotechnologies.
Istituto Italiano di Tecnologia is an Equal Opportunity Employer that actively seeks diversity in the workforce.
Please note that the data that you provide will be used exclusively for the purpose of professional profiles’ evaluation and selection, and in order to meet the requirements of Istituto Italiano di Tecnologia.
Your data will be processed by Istituto Italiano di Tecnologia, based in Genoa, Via Morego 30, acting as Data Controller, in compliance with the rules on protection of personal data, including those related to data security.